Werewolf Therapeutics (HOWL)
(Delayed Data from NSDQ)
$1.19 USD
-0.02 (-1.65%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $1.20 +0.01 (0.84%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HOWL 1.19 -0.02(-1.65%)
Will HOWL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HOWL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HOWL
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates
HOWL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline
Pacira (PCRX) Tops Q4 Earnings Estimates
MiMedx (MDXG) Q4 Earnings Meet Estimates
Other News for HOWL
Werewolf Therapeutics Adopts New Bylaws and Elects Directors
Werewolf Therapeutics (HOWL) Price Target Lowered by BofA, Buy Rating Maintained | HOWL Stock News
Werewolf Therapeutics price target lowered to $9 from $10 at BofA
Werewolf Therapeutics price target lowered by $1 at BofA, here's why
Bank of America Securities Remains a Buy on Werewolf Therapeutics (HOWL)